Mechanisms of K v2.1 channel inhibition by celecoxib - Modification of gating and channel block: RESEARCH PAPER

British Journal of Pharmacology

Volumn 159, Issue 2, 2010, Pages 405-418

  Frolov, R V ^a,b   Bondarenko, V E ^a,c   Singh, Satpal ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF OULU   (Finland)

^c GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Celebrex; Celecoxib; Closed channel block; Gating modification; K v2.1 channels; NSAID; Open channel block; Selective cyclooxygenase 2 inhibitor

Indexed keywords

CELECOXIB; POTASSIUM CHANNEL KV2.1; SHAB POTASSIUM CHANNEL; UNCLASSIFIED DRUG; CYCLOOXYGENASE 2 INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ARTICLE; CELL MEMBRANE TRANSPORT; CELL STRAIN HEK293; CHANNEL GATING; CONCENTRATION RESPONSE; CONTROLLED STUDY; CURVE FITTING; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TRANSPORT KINETICS; ANIMAL; CELL LINE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; PATCH CLAMP; PHYSIOLOGY; RAT;

ANIMALS; CELL LINE; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ION CHANNEL GATING; PATCH-CLAMP TECHNIQUES; PYRAZOLES; RATS; SHAB POTASSIUM CHANNELS; SULFONAMIDES;

EID: 75649132167     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00539.x     Document Type: Article

References (50)

1. Alexander SP, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edition. Br J Pharmacol 153 (Suppl. 2 S1 209.
2. v3.1/3.2 K(+) channels. J Neurosci 19 : 6394 6404.
3. v4-family transient potassium channels. Physiol Rev 84 : 803 833.
4. v1.5. J Pharmacol Exp Ther 275 : 864 876.
5. Brownstein JS, Sordo M, Kohane IS, Mandl KD (2007). The tell-tale heart: Population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction. PLoS ONE 2 : e840.
6. Burnier M (2005). The safety of rofecoxib. Expert Opin Drug Saf 4 : 491 499.
7. Chopra M, Gu GG, Singh S (2000). Mutations affecting the delayed rectifier potassium current in Drosophila. J Neurogenet 14 : 107 123.
8. Davies NM, McLachlan AJ, Day RO, Williams KM (2000). Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 38 : 225 242.
9. Flower RJ (2003). The development of COX2 inhibitors. Nat Rev Drug Discov 2 : 179 191.
10. Frolov RV, Slaughter MM, Singh S (2008a). Effects of celecoxib on ionic currents and spontaneous firing in rat retinal neurons. Neuroscience 154 : 1525 1532.
11. Frolov RV, Berim IG, Singh S (2008b). Inhibition of delayed rectifier potassium channels and induction of arrhythmia: a nosel effect of celecoxib and the mechanism underlying it. J Biol Chem 283 : 1518 1524.
12. v4.2 channel gating. Biophys J 86 : 210 223.
13. v1.5 channels. Mol Pharmacol 62 : 1456 1463.
14. Hegde P, Gu GG, Chen D, Free SJ, Singh S (1999). Mutational analysis of the Shab-encoded delayed rectifier K(+) channels in Drosophila. J Biol Chem 274 : 22109 22113.
15. Kalgutkar AS, Crews BC, Rowlinson SW, Garner C, Seibert K, Marnett LJ (1998). Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science 280 : 1268 1270.
16. v9.3: effect on the state dependence of inactivation. Biophys J 77 : 248 257.
17. v9.3. J Biol Chem 278 : 18154 18161.
18. v2.1 potassium channels. Biophys J 74 : 1779 1789.
19. Kurata HT, Soon GS, Eldstrom JR, Lu GW, Steele DF, Fedida D (2002). Amino-terminal determinants of U-type inactivation of voltage-gated K+ channels. J Biol Chem 277 : 29045 29053.
20. v2.1 to regulate channel gating and trafficking. J Biol Chem 278 : 17532 17538.
21. v2.1. Mol Pharmacol 63 : 547 556.
22. v2 alpha-subunits and regulate tonic firing in mammalian sympathetic neurons. J Neurosci 22 : 10094 10105.
23. Milnes JT, Dempsey CE, Ridley JM, Crociani O, Arcangeli A, Hancox JC et al. (2003). Preferential closed channel blockade of HERG potassium currents by chemically synthesised BeKm-1 scorpion toxin. FEBS Lett 547 : 20 26.
24. Misonou H, Mohapatra DP, Park EW, Leung V, Zhen D, Misonou K et al. (2004). Regulation of ion channel localization and phosphorylation by neuronal activity. Nat Neurosci 7 : 711 718.
25. v2.1: a voltage-gated k+ channel critical to dynamic control of neuronal excitability. Neurotoxicology 26 : 743 752.
26. v channels. J Neurosci 26 : 685 695.
27. v2.1 potassium channel by multisite phosphorylation. Biochem Soc Trans 35 : 1064 1068.
28. v2.1 K+ channel as a major component of the delayed rectifier K+ current in rat hippocampal neurons. J Neurosci 19 : 1728 1735.
29. O'Connell KM, Tamkun MM (2005). Targeting of voltage-gated potassium channel isoforms to distinct cell surface microdomains. J Cell Sci 118 : 2155 2166.
30. Ordog B, Brutyo E, Puskas LG, Papp JG, Varro A, Szabad J et al. (2006). Gene expression profiling of human cardiac potassium and sodium channels. Int J Cardiol 111 : 386 393.
31. v2.1 potassium channel by variable phosphorylation. Science 313 : 976 979.
32. Park SY, Kim TH, Kim HI, Shin YK, Lee CS, Park M et al. (2007). Celecoxib inhibits Na+ currents in rat dorsal root ganglion neurons. Brain Res 1148 : 53 61.
33. v9.3, a novel ATP-dependent delayed-rectifier K+ channel in oxygen-sensitive pulmonary artery myocytes. EMBO J 16 : 6615 6625.
34. Pinto LH, Klumpp DJ (1998). Localization of potassium channels in the retina. Prog Retin Eye Res 17 : 207 230.
35. v4.3: pore block and Ca2+-calmodulin inhibition. Am J Physiol Heart Circ Physiol 292 : H2364 2377.
36. Singh A, Singh S (1999). Unmasking of a novel potassium current in Drosophila by a mutation and drugs. J Neurosci 19 : 6838 6843.
37. Singh G, Triadafilopoulos G (1999). Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 56 : 18 24.
38. v2.1 potassium channels. Eur Biophys J 34 : 42 51.
39. VanDongen AM, Frech GC, Drewe JA, Joho RH, Brown AM (1990). Alteration and restoration of K+ channel function by deletions at the N- and C-termini. Neuron 5 : 433 443.
40. v10 subunits. Brain Res Mol Brain Res 123 : 91 103.
41. v1.4 channel block by quinidine: evidence for a drug-induced allosteric effect. J Physiol 546 : 387 401.
42. v4.3 channels: time, voltage and [K+]o dependence. J Physiol 557 : 705 717.
43. v2.1 K+ channels underlie major voltage-gated K+ outward current in H9c2 myoblasts. Jpn J Physiol 52 : 507 514.
44. Wareing M, Bai X, Seghier F, Turner CM, Greenwood SL, Baker PN et al. (2006). Expression and function of potassium channels in the human placental vasculature. Am J Physiol Regul Integr Comp Physiol 291 : R437 R446.
45. Weber A, Casini A, Heine A, Kuhn D, Supuran CT, Scozzafava A et al. (2004). Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem 47 : 550 557.
46. Wit AL, Rosen MR (1992). After depolarizations and triggered activity: distinction from automaticity as an arrhythmogenic mechanism. In : Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE (eds). The Heart and Cardiovascular System. Raven Press : New York, pp. 2113 2164.
47. v2 alpha subunit. Circ Res 85 : 623 633.
48. Yan L, Figueroa DJ, Austin CP, Liu Y, Bugianesi RM, Slaughter RS et al. (2004). Expression of voltage-gated potassium channels in human and rhesus pancreatic islets. Diabetes 53 : 597 607.
49. v1.5 potassium channels. Brain Res Mol Brain Res 131 : 136 140.
50. Zhang Y, Tao J, Huang H, Ding G, Cheng Y, Sun W (2007). Effects of celecoxib on voltage-gated calcium channel currents in rat pheochromocytoma (PC12) cells. Pharmacol Res 56 : 267 274.